100 Days Mission

Scorecard 3.0

IPPS

Impact
Global
Health

INDICATOR	CORONAVIRIDAE		FILOVIRIDAE		NAIROVIRIDAE	PHENUIVIRIDAE	ARENAVIRIDAE	PARAMYXOVIRIDAE	FLAVIVIRIDAE	TOGAVIRIDAE	POXVIRIDAE	HANTAVIRIDAE	ORTHOMYXOVIRIDAE
	COVID-19	MERS-CoV	Ebola	Marburg	CCHF	RVF	Lassa Fever	Nipah	Zika	Chikungunya	Mpox	Hantaan (new)	H5N1 (new)

NOW

R&D funding for diagnostics, therapeutics and vaccines (2021-2024)

	COVID-19	MERS-CoV	Ebola	Marburg	CCHF	RVF	Lassa Fever	Nipah	Zika	Chikungunya	Mpox	Hantaan (new)	H5N1 (new)
Δ from 2023	▼	▲	▼	▼	▲	▲	▼	▼	▼	▼	▲	*only 2024 funding data available	*only 2024 funding data available
Amount	$15bn	$29m	$488m	$260m	$41m	$33m	$86m	$136m	$172m	$143m	$138m *only 2023-2024 funding data available	$7.5m	$40m

COVID-19: 45%, 43%, 9%, 3% — Aggregate industry, US government, German government, Other
MERS-CoV: 97%, 16%, 4%, 3%, 1.4%, 1.3%, 0.8% — US government, Aggregate industry, Samsung Foundation, Other
Ebola: 76% — US government, Aggregate industry, European Commission, Other
Marburg: 99.7%, 0.3% — US government, UK government
CCHF: 77%, 11%, 8%, 4% — US government, European Commission, UK government, Other
RVF: 72%, 25%, 3%, 1% — European Commission, US government, UK government, Other
Lassa Fever: 98%, 1.3%, 0.3%, 0.2% — US government, Wellcome, Korea mRNA Vaccine Initiative, Other
Nipah: 89%, 6%, 4%, 1% — US government, Aggregate industry, Gates Foundation, Other
Zika: 86%, 6%, 5%, 2% — US government, Aggregate industry, Colombian government, Other
Chikungunya: 39%, 34%, 23%, 4% — US government, Aggregate industry, European Commission, Other
Mpox: 65%, 27%, 4%, 4% — US government, Aggregate industry, UK government, Other
Hantaan: 100% — US government
H5N1: 54%, 43%, 2%, 0.5% — Aggregate industry, US government, Canadian government, Other

Approved products

Legend: No approved product / Product approved / Product approved in LMIC
(Dx, Vx, Thx segments per disease)

FUTURE READINESS

Candidates tested in humans

Phase	COVID-19 Vx/Thx	MERS-CoV Vx/Thx	Ebola Vx/Thx	Marburg Vx/Thx	CCHF Vx/Thx	RVF Vx/Thx	Lassa Vx/Thx	Nipah Vx/Thx	Zika Vx/Thx	Chikungunya Vx/Thx	Mpox Vx/Thx	Hantaan Vx/Thx	H5N1 Vx/Thx
III	11 / 6	0 / 0	1 / 4	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	1 / 1	1 / 1	1 / 1	0 / 0	0 / 0
II	17 / 4	0 / 0	1 / 0	1 / 1	0 / 2	2 / 0	1 / 3	0 / 0	1 / 0	1 / 0	2 / 1	0 / 0	3 / 0
I	15 / 5	2 / 0	3 / 1	3 / 1	4 / 0	1 / 1	2 / 1	4 / 1	6 / 0	3 / 2	1 / 0	0 / 0	7 / 0
Late stage Dx	84	1	3	0	2	0	0	0	2	5	27	0	0

Legend: No change in candidates / Increase in candidates / Decrease in candidates

Platform technologies used in clinical candidates

Legend: No platform technology used / Less than three platform technologies used / Three or more platform technologies used / New platform technologies used, less than three / New platform technologies used, three or more / Decrease to no platform technology used / Decrease to less than three platform technologies used

Disease X R&D funding (2021-2024)

DIAGNOSTIC PLATFORMS — Δ from 2023: ▲ $421m
77%, 12%, 6%, 5% — US government, Gates Foundation, European Commission, Other

THERAPEUTIC PLATFORMS — Δ from 2023: ▲ $1bn
84%, 10%, 3%, 3% — US government, Gates Foundation, European Commission, Other

VACCINE PLATFORMS — Δ from 2023: ▲ $862m
52%, 38%, 6%, 4% — US government, Gates Foundation, Aggregate industry, Other

R&D ENABLERS

	COVID-19	MERS-CoV	Ebola	Marburg	CCHF	RVF	Lassa Fever	Nipah	Zika	Chikungunya	Mpox	Hantaan	H5N1
Use of animal rule to support licensure	✘	✘	✔	✘	✘	✘	✘	✘	✘	✘	✘	✘	✘
Correlates of protection	✔	✘	✘	✘	✘	✘	✘	✘	✘	✘	✘	✘	✘
WHO Target Product Profiles — Vx	✔	✔	✔	✔	✘	✘	✔	✘	✔	✘	✔	✘	✘
WHO Target Product Profiles — Thx	✘	✘	✘	✘	✘	✘	✘	✘	✘	✘	✔	✘	✘
WHO Target Product Profiles — Dx	✔	✘	✘	✘	✘	✘	✘	✘	✘	✘	✘	✘	✘

Legend: No change in enablers in 2024 vs 2023 / New enablers in 2024 vs 2023 / ▲ Increase in funding in 2024 vs 2023 / ▼ Decrease in funding in 2024 vs 2023 / 🏛 Highlights US government's leading role in this space / $ = US dollars / Vx - Vaccines; Thx - Therapeutics; Dx - Diagnostics / Due to rounding percentage totals may appear to exceed 100%